January 17, 2023

George Vradenburg and the Future of Alzheimer's Advocacy - Part 1

George Vradenburg and the Future of Alzheimer's Advocacy - Part 1

About This Episode

The Food and Drug Administration expedited approval of Lecanemab, a drug developed by Eisai and Biogen, that demonstrated positive results in slowing Alzheimer's disease. What does this mean for the future of Alzheimer’s advocacy?

In this episode of BrainStorm, host Meryl Comer talks with George Vradenburg, Chairman and Co-Founder of UsAgainstAlzheimer’s, Convener of Global CEOi and Co-Convener with the World Economic Forum of the Davos Alzheimer’s Collaborative.  They discuss the immediate implications of the drug approval, how it will impact the Alzheimer’s movement, and what it means for the future of Alzheimer’s disease. 

Do you have feedback or an idea for the podcast? Send us a note at [email protected].
 

Support the show

BrainStorm Feed

92

Navigating Alzheimer's Care: When to Seek Help and How to Stay in Control with Dr. Carolyn Clevenger

In this episode of BrainStorm by UsAgainstAlzheimer’s Dr. Carolyn Clevenger, Founder and Director of Emory's innovative Integrated Memory Care Clinic continues to explore the complex realities of Alzheimer's caregiving with host Meryl Comer.
LISTEN NOW
91

Managing Agitation in Dementia: Expert Insights on Integrated Care and Caregiver Support with Dr. Carolyn Clevenger (part 1)

In this episode of BrainStorm by UsAgainstAlzheimer's, host Meryl Comer explores the critical issue of agitation in dementia care with Dr. Carolyn Clevenger, Founder and Director of Emory's Integrated Memory Care Clinic.
LISTEN NOW
90

The Longevity Paradox: Health Span vs. Life Span with Paul Irving

What's the purpose of a long life if our brains can't enjoy it? Paul Irving, Senior Advisor at the Milken Institute on the Future of Longevity and Dean of Faculty at USC's Leonard Davis School of Gerontology, challenges conventional thinking about aging and longevity in a conversation with host, Meryl Comer.
LISTEN NOW